Technetium-99m DTPA: A New Radiopharmaceutical for Brain and Kidney Scanning

Abstract

Technetium 99m was combined with the chelating agent DTPA in order to obtain a scanning agent with the physical properties of the radionuclide technetium 99m and the desirable biological properties of chelating agents. The method for the preparation of the chelate is described. No toxic effects are expected. About 90 per cent of the compound is eliminated by the kidneys in twenty-four hours. The absorbed radiation dose is 0.042 rad/mCi by the kidneys and 0.555 rad/mCi by the bladder. In clinical studies the chelate is useful for scanning of brain and kidneys and for vascular dynamic studies.